Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Operating Income (2019 - 2025)

Benitec Biopharma's Operating Income history spans 7 years, with the latest figure at -$10.2 million for Q1 2025.

  • For Q1 2025, Operating Income fell 146.03% year-over-year to -$10.2 million; the TTM value through Mar 2025 reached -$32.3 million, down 50.44%, while the annual FY2024 figure was -$22.5 million, 17.87% down from the prior year.
  • Operating Income for Q1 2025 was -$10.2 million at Benitec Biopharma, up from -$10.8 million in the prior quarter.
  • Across five years, Operating Income topped out at -$3.5 million in Q1 2022 and bottomed at -$10.8 million in Q4 2024.
  • The 5-year median for Operating Income is -$4.8 million (2021), against an average of -$5.5 million.
  • The largest annual shift saw Operating Income increased 8.81% in 2022 before it crashed 146.03% in 2025.
  • A 5-year view of Operating Income shows it stood at -$4.8 million in 2021, then dropped by 16.03% to -$5.6 million in 2022, then dropped by 23.48% to -$6.9 million in 2023, then plummeted by 55.98% to -$10.8 million in 2024, then increased by 5.71% to -$10.2 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Operating Income are -$10.2 million (Q1 2025), -$10.8 million (Q4 2024), and -$5.8 million (Q3 2024).